Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer

Wei Chung Hsieh, Ya Wen Cheng, Cuei Iyuan Lin, Ming Chih Chou, Chih Yi Chen, Huei Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: A novel T-77C polymorphism in the promoter region of the DNA repair gene X-ray cross-complementing group 1 (XRCC1) may modulate its transcription to increase the risk of lung cancer. Here, we attempt to clarify: (i) whether the XRCC1 T-77C polymorphism was associated with lung cancer risk in Taiwanese and (ii) whether this polymorphism could act as a prognostic indicator to predict the clinical outcome of non-small-cell lung cancer (NSCLC) patients. Methods: A total of 294 primary lung cancer patients and 288 potential controls were recruited into our study. Clinical data were collected. The genotypes of XRCC1 T-77C were identified by polymerase chain reaction. Results: Our case-control study showed that the XRCC1 T-77C polymorphism was not associated with the risk of lung cancer in Taiwanese patients. To verify the impact of the XRCC1 T-77C polymorphism on the clinical outcome of NSCLC, survival analysis showed that patients with TT had a lower survival rate than those with the TC + CC genotype (33.1% versus 48.8%, P = 0.031). The Cox regression analysis further indicated that patients with the TT genotype had a 1.84-fold risk compared with those with the TC + CC genotype (95% CI, 1.16-2.86, P = 0.008). Conclusion: Our results suggest that XRCC1 T-77C variants (TC + CC) may act as a favorable prognostic indicator of resected NSCLC.

Original languageEnglish
Pages (from-to)81-85
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume39
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
X-Rays
Lung Neoplasms
Genotype
Survival Analysis
Genetic Promoter Regions
DNA Repair
Case-Control Studies
Survival Rate
Regression Analysis
Polymerase Chain Reaction
Genes

Keywords

  • NSCLC
  • Prognosis
  • XRCC1 genetic polymorphism

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer. / Hsieh, Wei Chung; Cheng, Ya Wen; Lin, Cuei Iyuan; Chou, Ming Chih; Chen, Chih Yi; Lee, Huei.

In: Japanese Journal of Clinical Oncology, Vol. 39, No. 2, 2009, p. 81-85.

Research output: Contribution to journalArticle

Hsieh, Wei Chung ; Cheng, Ya Wen ; Lin, Cuei Iyuan ; Chou, Ming Chih ; Chen, Chih Yi ; Lee, Huei. / Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer. In: Japanese Journal of Clinical Oncology. 2009 ; Vol. 39, No. 2. pp. 81-85.
@article{0d68aa2a150640d581369d9df8b62241,
title = "Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer",
abstract = "Objective: A novel T-77C polymorphism in the promoter region of the DNA repair gene X-ray cross-complementing group 1 (XRCC1) may modulate its transcription to increase the risk of lung cancer. Here, we attempt to clarify: (i) whether the XRCC1 T-77C polymorphism was associated with lung cancer risk in Taiwanese and (ii) whether this polymorphism could act as a prognostic indicator to predict the clinical outcome of non-small-cell lung cancer (NSCLC) patients. Methods: A total of 294 primary lung cancer patients and 288 potential controls were recruited into our study. Clinical data were collected. The genotypes of XRCC1 T-77C were identified by polymerase chain reaction. Results: Our case-control study showed that the XRCC1 T-77C polymorphism was not associated with the risk of lung cancer in Taiwanese patients. To verify the impact of the XRCC1 T-77C polymorphism on the clinical outcome of NSCLC, survival analysis showed that patients with TT had a lower survival rate than those with the TC + CC genotype (33.1{\%} versus 48.8{\%}, P = 0.031). The Cox regression analysis further indicated that patients with the TT genotype had a 1.84-fold risk compared with those with the TC + CC genotype (95{\%} CI, 1.16-2.86, P = 0.008). Conclusion: Our results suggest that XRCC1 T-77C variants (TC + CC) may act as a favorable prognostic indicator of resected NSCLC.",
keywords = "NSCLC, Prognosis, XRCC1 genetic polymorphism",
author = "Hsieh, {Wei Chung} and Cheng, {Ya Wen} and Lin, {Cuei Iyuan} and Chou, {Ming Chih} and Chen, {Chih Yi} and Huei Lee",
year = "2009",
doi = "10.1093/jjco/hyn130",
language = "English",
volume = "39",
pages = "81--85",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer

AU - Hsieh, Wei Chung

AU - Cheng, Ya Wen

AU - Lin, Cuei Iyuan

AU - Chou, Ming Chih

AU - Chen, Chih Yi

AU - Lee, Huei

PY - 2009

Y1 - 2009

N2 - Objective: A novel T-77C polymorphism in the promoter region of the DNA repair gene X-ray cross-complementing group 1 (XRCC1) may modulate its transcription to increase the risk of lung cancer. Here, we attempt to clarify: (i) whether the XRCC1 T-77C polymorphism was associated with lung cancer risk in Taiwanese and (ii) whether this polymorphism could act as a prognostic indicator to predict the clinical outcome of non-small-cell lung cancer (NSCLC) patients. Methods: A total of 294 primary lung cancer patients and 288 potential controls were recruited into our study. Clinical data were collected. The genotypes of XRCC1 T-77C were identified by polymerase chain reaction. Results: Our case-control study showed that the XRCC1 T-77C polymorphism was not associated with the risk of lung cancer in Taiwanese patients. To verify the impact of the XRCC1 T-77C polymorphism on the clinical outcome of NSCLC, survival analysis showed that patients with TT had a lower survival rate than those with the TC + CC genotype (33.1% versus 48.8%, P = 0.031). The Cox regression analysis further indicated that patients with the TT genotype had a 1.84-fold risk compared with those with the TC + CC genotype (95% CI, 1.16-2.86, P = 0.008). Conclusion: Our results suggest that XRCC1 T-77C variants (TC + CC) may act as a favorable prognostic indicator of resected NSCLC.

AB - Objective: A novel T-77C polymorphism in the promoter region of the DNA repair gene X-ray cross-complementing group 1 (XRCC1) may modulate its transcription to increase the risk of lung cancer. Here, we attempt to clarify: (i) whether the XRCC1 T-77C polymorphism was associated with lung cancer risk in Taiwanese and (ii) whether this polymorphism could act as a prognostic indicator to predict the clinical outcome of non-small-cell lung cancer (NSCLC) patients. Methods: A total of 294 primary lung cancer patients and 288 potential controls were recruited into our study. Clinical data were collected. The genotypes of XRCC1 T-77C were identified by polymerase chain reaction. Results: Our case-control study showed that the XRCC1 T-77C polymorphism was not associated with the risk of lung cancer in Taiwanese patients. To verify the impact of the XRCC1 T-77C polymorphism on the clinical outcome of NSCLC, survival analysis showed that patients with TT had a lower survival rate than those with the TC + CC genotype (33.1% versus 48.8%, P = 0.031). The Cox regression analysis further indicated that patients with the TT genotype had a 1.84-fold risk compared with those with the TC + CC genotype (95% CI, 1.16-2.86, P = 0.008). Conclusion: Our results suggest that XRCC1 T-77C variants (TC + CC) may act as a favorable prognostic indicator of resected NSCLC.

KW - NSCLC

KW - Prognosis

KW - XRCC1 genetic polymorphism

UR - http://www.scopus.com/inward/record.url?scp=59349097419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59349097419&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyn130

DO - 10.1093/jjco/hyn130

M3 - Article

VL - 39

SP - 81

EP - 85

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -